Welcome to the 510th Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past week.
The highlights of this week's edition are randomised controlled trials on remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 & inhaled amikacin versus placebo to prevent ventilator-associated pneumonia; systematic reviews and meta analyses on liberal or conservative oxygen therapy for ventilated patients in the ICU & hemodynamic monitoring in patients with subarachnoid hemorrhage; and observational studies on the association of the COVID-19 pandemic and short-term outcomes of non-COVID-19 critically ill patients & critical illness in patients with hematologic malignancy. There are also guidelines on the management of left ventricular assist device supported patients for the non-LVAD specialist & difficult airway management in adult Coronavirus disease patients; narrative reviews on 50 years of sepsis investigation/enlightenment among adults & surviving sepsis campaign: research opportunities for infection and blood purification therapies; commentaries on critical care archetypes & the management of multi-morbidity in elderly patients; as well as correspondence on interleukin-6 receptor antagonists in critically ill patients with Covid-19 & the use of stylet and airway management procedures in critically ill patients.
If you only have time to read one review article this week, try this one on persistent air leak management in critically ill patients.
VAM-ICHA Trial Results Livestream
On Wednesday, September 29th (Thursday morning in the Pacific & East Asia), we host the trial results livestream of the VAM-ICHA trial, investigating vasopressin and methylprednisolone for in-hospital cardiac arrest. The independent editorial will be delivered by Prof Spyros Mentzelopoulos, the lead investigator for the original VSE trial, published in JAMA in 2013. The livestream begins at 19:30 UTC+1, and will be freely available at Critical Care Reviews. If you have any questions for the trialists (Lars Wiuff Andersen & Asger Granfeldt), you can reply to this email, post them on the chat function during the livestream or use twitter (@critcarereviews).